Consistently, AFP showed much poorer diagnostic performance than the biomarker panel in discriminating early-stage MetS(+) HCC from MetS, and the AUC, sensitivity and specificity were 0.63, 50.00% and 76.00%, respectively (Figure 5E and Table 4). This evidence concerns the gene AFP and metabolic syndrome.